Using low-cost tests to improve surveillance of vaccine-preventable diseases.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance the surveillance of vaccine-preventable diseases (VPDs) in Italy by utilizing low-cost molecular diagnostic techniques, such as real-time PCR, to improve the identification of pathogens. The research will involve analyzing biological samples from children aged 0-18 years diagnosed with infectious diseases at the AOU Meyer Immunology Laboratory. By increasing the sensitivity of pathogen detection, the study seeks to provide better epidemiological data and inform vaccination strategies. The multicenter approach will allow for a broader assessment of VPD incidence across different regions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects aged 0-18 years with infectious disease (bacterial or viral) diagnosed by molecular techniques at the AOU Meyer Immunology Laboratory
* Obtaining informed consent

Exclusion Criteria:

* Individuals with concomitant diseases such as cystic fibrosis, known immunodeficiency, or with infection suspected nosocomial (hospitalization or hospital admission within 15 days prior to the onset of symptoms) will be excluded from the study

Where it's running

• Ospedale San Donato
  Arezzo, Italy Recruiting
• Immunology Laboratory Meyer Children's Hospital, IRCCS
  Florence, Italy Recruiting
• Meyer Children's Hospital IRCCS
  Florence, Italy Recruiting
• UO Pediatria Universitaria Ospedale S.Chiara
  Pisa, Italy Recruiting

Study contacts

• Principal investigator: Massimo Resti — Meyer Children's Hospital IRCCS
• Study coordinator: Massimo Resti
• Email: massimo.resti@meyer.it
• Phone: 0555662566

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

• Personalized beta-lactam dosing in cirrhosis patients with bacterial infections

  This study tests whether tailoring beta-lactam dosing based on patient liver disease and drug levels can help people with cirrhosis and bacterial infections.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07612163

• Vaginitis Diagnostic Algorithm Pilot Using Nanopath and Other Tests

  This study tests a new Nanopath vaginal test to see if it correctly detects vaginitis-causing pathogens in up to 1,000 people with vaginitis symptoms.

  Recruiting at 2 sites Nanopath, Inc · North Miami, Florida and 1 other locations · NCT07607470

• Testing single and multiple IV doses of JKN2501 in healthy Chinese adults

  This test gives single and multiple intravenous doses of JKN2501 to healthy Chinese adults to see if it's safe and how the body processes it.

  Recruiting Phase 1 Joincare Pharmaceutical Group Industry Co., Ltd · Changsha, Hunan · NCT07207291

• Tracking acute treatment and long-term outcomes in children with meningitis

  This registry will collect care and outcome information to see how current treatments affect short- and long-term outcomes in children under 18 with suspected meningitis in Brazil.

  Recruiting Hospital Israelita Albert Einstein · São Paulo, São Paulo · NCT07062445

• Single antibiotic versus two antibiotics for Pseudomonas bone infection

  This study will test whether one antibiotic works as well as two for adults with bone infections caused by Pseudomonas aeruginosa.

  Recruiting Centre Hospitalier de Saint-Denis · Saint-Denis, France · NCT07056881

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.